创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: What are the characteristics of humanized model of immune system?

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-15 16:05
  • Views:

(Summary description)As a specialized, special and new enterprise in Beijing, InnoModels Biotechnology (Beijing) Co., Ltd. has been working in the field of humanized models of the immune system since its establishment, and has continuously promoted the research, development and application of related technologies. The humanized immune system model developed by the company has successfully rebuilt the human immune system in mice by transplanting human immune cells or precursor cells into mice, providing unprecedented experimental means for drug research and development, tumor immunotherapy and other fields.

InnoModels Biotechnology: What are the characteristics of humanized model of immune system?

(Summary description)As a specialized, special and new enterprise in Beijing, InnoModels Biotechnology (Beijing) Co., Ltd. has been working in the field of humanized models of the immune system since its establishment, and has continuously promoted the research, development and application of related technologies. The humanized immune system model developed by the company has successfully rebuilt the human immune system in mice by transplanting human immune cells or precursor cells into mice, providing unprecedented experimental means for drug research and development, tumor immunotherapy and other fields.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-15 16:05
  • Views:
Information

As a specialized, special and new enterprise in Beijing, InnoModels Biotechnology (Beijing) Co., Ltd. has been working in the field of humanized models of the immune system since its establishment, and has continuously promoted the research, development and application of related technologies. The humanized immune system model developed by the company has successfully rebuilt the human immune system in mice by transplanting human immune cells or precursor cells into mice, providing unprecedented experimental means for drug research and development, tumor immunotherapy and other fields.
The humanized immune system model of InnoModels has remarkable features. Firstly, it realizes the stable reconstruction of the immune system. Traditional animal models are often difficult to fully simulate the human immune system, resulting in large discrepancies between experimental results and clinical data. However, the modeling success rate of the biomimetic model has been improved from 50% to 87%, and the coefficient of variation within the group has also been greatly reduced, which makes the experimental results more reliable and stable.
Secondly, the model of InnoModels is able to reconstruct multiple immune cells. In previous models, only T-cells can be successfully reconstructed in mice. However, the model breaks through this limitation and can reconstruct a variety of immune cells, including T cells, B cells, NK cells, macrophages, DC cells, etc., thus more realistically simulating the complexity of the human immune system.

 


In addition, the number of immune cells reconstructed in the model of InnoModels Biotechnology can reach or approach the concentration of human immune cells. This means that the model can provide a more realistic environment for drug testing, enabling drugs to be evaluated under conditions closer to the actual human condition before entering clinical trials, thus improving the efficiency and success rate of drug development.
In order to meet the needs of different fields, InnoModels Biotechnology also provides customers with several sub-platforms. Among them, the iHuPBMC-T platform is designed for T-cell immunotherapy, which is able to simulate the behavior of human T-cells in the tumor microenvironment, providing strong support for T-cell immunotherapy research and development. In addition, InnoModels Biotechnology has also launched the PBMC-PDX Dual Derivative Model, which can be modeled using tumors and PBMCs originating from the same patient, making the experimental results closer to the clinical reality.
It is worth mentioning that InnoModels' PBMC-PDX model has successfully solved the major problems of tumor growth and PBMC antagonism and cycle matching in immune system tumor models, significantly improving the success rate of experiments and overcoming the problem of short drug delivery window due to graft-versus-host disease. This makes the model have higher application value in the development of tumor immunity drugs.
Overall, the humanized model of the immune system of InnoModels Biotechnology shows great potential in the fields of drug discovery and tumor immunotherapy due to its stability, multicellular reconstruction, and proximity to human body concentration. Meanwhile, the multiple sub-platforms it provides also meet the needs of different fields, providing scientists with richer and more efficient experimental means. It is believed that in the future, InnoModels Biotechnology will continue to make innovations and breakthroughs in the field of humanized models of the immune system, and make greater contributions to the cause of human health.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司